(THC) Tenet Healthcare - Overview
Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 16.940m USD | Total Return: 17.6% in 12m
Hospital Services, Ambulatory Care, Surgical Procedures, Diagnostic Imaging
Total Rating 52
Safety 70
Buy Signal -0.26
Medical Care Facilities
Industry Rotation: +12.2
Industry Rotation: +12.2
Market Cap:
16.9B
Avg Turnover: 287M
Avg Turnover: 287M
Risk 3d forecast
Volatility35.0%
VaR 5th Pctl6.06%
VaR vs Median5.15%
Reward TTM
Sharpe Ratio0.55
Rel. Str. IBD33
Rel. Str. Peer Group58.3
Character TTM
Beta1.114
Beta Downside0.945
Hurst Exponent0.605
Drawdowns 3y
Max DD36.90%
CAGR/Max DD1.07
CAGR/Mean DD4.09
EPS (Earnings per Share)
EPS CAGR: 36.52%
EPS Trend: 87.9%
EPS Trend: 87.9%
Last SUE: 0.78
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: 3.97%
Rev. Trend: 79.8%
Rev. Trend: 79.8%
Last SUE: -0.28
Qual. Beats: 0
Qual. Beats: 0
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Description: THC Tenet Healthcare
Tenet Healthcare Corporation (THC) is a Dallas-based healthcare services provider operating through two primary segments: Hospital Operations and Ambulatory Care. The company manages a network of acute care hospitals, specialty facilities, and surgical centers that provide a range of services from routine outpatient diagnostics to complex quaternary care, including organ transplants and level 1 trauma support.
The business model increasingly emphasizes ambulatory surgery centers (ASCs), which typically offer higher margins and lower overhead costs compared to traditional inpatient hospital settings. Within the Health Care Facilities sub-industry, providers are currently navigating a structural shift toward value-based care and outpatient migration to offset rising labor costs in acute care environments.
Investors can evaluate the underlying valuation metrics and historical performance of THC on ValueRay. Founded in 1967, the company maintains a diversified geographic footprint, utilizing advanced medical technologies such as surgical robotics and telemedicine to service patient populations across the United States.
- USPI ambulatory surgery center expansion drives higher-margin outpatient revenue growth
- Strategic hospital divestitures reduce debt leverage and improve consolidated margins
- Medicare reimbursement rate adjustments impact core acute care services profitability
- Rising clinical labor costs and nursing shortages pressure hospital operating margins
- Population aging in core sunbelt markets increases demand for high-acuity surgeries
Piotroski VR‑10 (Strict)
8.5
| Net Income: 1.70b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 5.87 > 1.0 |
| NWC/Revenue: 10.27% < 20% (prev 16.87%; Δ -6.60% < -1%) |
| CFO/TA 0.14 > 3% & CFO 4.37b > Net Income 1.70b |
| Net Debt (10.24b) to EBITDA (4.40b): 2.33 < 3 |
| Current Ratio: 1.36 > 1.5 & < 3 |
| Outstanding Shares: last quarter (87.6m) vs 12m ago -7.81% < -2% |
| Gross Margin: 42.76% > 18% (prev 0.40%; Δ 4.24k% > 0.5%) |
| Asset Turnover: 71.00% > 50% (prev 70.19%; Δ 0.81% > 0%) |
| Interest Coverage Ratio: 4.28 > 6 (EBITDA TTM 4.40b / Interest Expense TTM 822.0m) |
Altman Z''
2.01
| A: 0.07 (Total Current Assets 8.36b - Total Current Liabilities 6.15b) / Total Assets 31.20b |
| B: 0.16 (Retained Earnings 5.12b / Total Assets 31.20b) |
| C: 0.12 (EBIT TTM 3.52b / Avg Total Assets 30.22b) |
| D: 0.22 (Book Value of Equity 4.95b / Total Liabilities 22.35b) |
| Altman-Z'' Score: 2.01 = BBB |
Beneish M
-3.30
| DSRI: 0.79 (Receivables 2.60b/3.15b, Revenue 21.45b/20.52b) |
| GMI: 0.94 (GM 42.76% / 40.38%) |
| AQI: 1.01 (AQ_t 0.53 / AQ_t-1 0.52) |
| SGI: 1.05 (Revenue 21.45b / 20.52b) |
| TATA: -0.09 (NI 1.70b - CFO 4.37b) / TA 31.20b) |
| Beneish M-Score: -3.30 (Cap -4..+1) = AA |
What is the price of THC shares?
As of May 18, 2026, the stock is trading at USD 196.66 with a total of 1,657,771 shares traded.
Over the past week, the price has changed by +3.30%, over one month by +0.01%, over three months by -16.05% and over the past year by +17.56%.
Over the past week, the price has changed by +3.30%, over one month by +0.01%, over three months by -16.05% and over the past year by +17.56%.
Is THC a buy, sell or hold?
Tenet Healthcare has received a consensus analysts rating of 4.32.
Therefore, it is recommended to buy THC.
- StrongBuy: 12
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the THC price?
| Analysts Target Price | 245.5 | 24.8% |
Tenet Healthcare (THC) - Fundamental Data Overview
as of 18 May 2026
P/E Trailing = 10.2267 P/E Forward = 11.274
P/S = 0.7895
P/B = 3.4065
P/EG = 4.698
Revenue TTM = 21.45b USD
EBIT TTM = 3.52b USD
EBITDA TTM = 4.40b USD
Long Term Debt = 13.13b USD (from longTermDebt, last quarter)
Short Term Debt = 81.0m USD (from shortTermDebt, last quarter)
Debt = 13.21b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.24b USD (from netDebt column, last quarter)
Enterprise Value = 27.18b USD (16.94b + Debt 13.21b - CCE 2.97b)
Interest Coverage Ratio = 4.28 (Ebit TTM 3.52b / Interest Expense TTM 822.0m)
EV/FCF = 8.12x (Enterprise Value 27.18b / FCF TTM 3.35b)
FCF Yield = 12.32% (FCF TTM 3.35b / Enterprise Value 27.18b)
FCF Margin = 15.61% (FCF TTM 3.35b / Revenue TTM 21.45b)
Net Margin = 7.94% (Net Income TTM 1.70b / Revenue TTM 21.45b)
Gross Margin = 42.76% ((Revenue TTM 21.45b - Cost of Revenue TTM 12.28b) / Revenue TTM)
Gross Margin QoQ = 16.43% (prev 15.72%)
Tobins Q-Ratio = 0.87 (Enterprise Value 27.18b / Total Assets 31.20b)
Interest Expense / Debt = 1.55% (Interest Expense 205.0m / Debt 13.21b)
Taxrate = 19.96% (226.0m / 1.13b)
NOPAT = 2.81b (EBIT 3.52b * (1 - 19.96%))
Current Ratio = 1.36 (Total Current Assets 8.36b / Total Current Liabilities 6.15b)
Debt / Equity = 2.74 (Debt 13.21b / totalStockholderEquity, last quarter 4.81b)
Debt / EBITDA = 2.33 (Net Debt 10.24b / EBITDA 4.40b)
Debt / FCF = 3.06 (Net Debt 10.24b / FCF TTM 3.35b)
Total Stockholder Equity = 4.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.64% (Net Income 1.70b / Total Assets 31.20b)
RoE = 40.55% (Net Income TTM 1.70b / Total Stockholder Equity 4.20b)
RoCE = 20.30% (EBIT 3.52b / Capital Employed (Equity 4.20b + L.T.Debt 13.13b))
RoIC = 16.19% (NOPAT 2.81b / Invested Capital 17.38b)
WACC = 6.11% (E(16.94b)/V(30.15b) * Re(9.90%) + D(13.21b)/V(30.15b) * Rd(1.55%) * (1-Tc(0.20)))
Discount Rate = 9.90% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -100.00 | Cagr: -7.41%
[DCF] Terminal Value 88.06% ; FCFF base≈2.58b ; Y1≈3.18b ; Y5≈5.43b
[DCF] Fair Price = 1.64k (EV 151.91b - Net Debt 10.24b = Equity 141.67b / Shares 86.1m; r=6.11% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 87.95 | EPS CAGR: 36.52% | SUE: 0.78 | # QB: 0
Revenue Correlation: 79.81 | Revenue CAGR: 3.97% | SUE: -0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=4.19 | Chg30d=-1.47% | Revisions=-20% | Analysts=19
EPS next Quarter (2026-09-30): EPS=4.11 | Chg30d=+0.56% | Revisions=-5% | Analysts=19
EPS current Year (2026-12-31): EPS=17.79 | Chg30d=+3.78% | Revisions=+65% | GrowthEPS=+6.0% | GrowthRev=+3.2%
EPS next Year (2027-12-31): EPS=17.82 | Chg30d=+1.49% | Revisions=+36% | GrowthEPS=+0.1% | GrowthRev=+1.6%
[Analyst] Revisions Ratio: +65%